Skip to Main Content

Paper Details

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD.
medRxiv
30
2021
Author NameAffiliation
Ana S Gonzalez-ReicheIcahn School of Medicine at Mount Sinai
Harm van BakelIcahn School of Medicine at Mount Sinai
Harm van BakelIcahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai
Harm van BakelIcahn School of Medicine at Mount Sinai
Harm van BakelIcahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai
Goran BajicIcahn School of Medicine at Mount Sinai
Viviana SimonIcahn School of Medicine at Mount Sinai
Viviana SimonIcahn School of Medicine at Mount Sinai
Viviana SimonThe Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 9

Datasets

Release 1.2